HBK Investments’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-20,000
Closed -$32K 854
2021
Q3
$32K Sell
20,000
-38,599
-66% -$53.2K ﹤0.01% 700
2021
Q2
$101K Hold
58,599
﹤0.01% 737
2021
Q1
$79K Sell
58,599
-4,900
-8% -$9.09K ﹤0.01% 766
2020
Q4
$124K Hold
63,499
﹤0.01% 668
2020
Q3
$108K Sell
63,499
-56,461
-47% -$92.7K ﹤0.01% 608
2020
Q2
$176K Buy
+119,960
New +$172K ﹤0.01% 536

Other funds holding STLNW

HBK Investments's STLNW Position: Q1 2022 in Review

HBK Investments sold out of Starling Oncology, Inc. Warrant (STLNW) in Q1 2022, closing a stake of 14,000 shares — an estimated $10K sold.

HBK Investments first reported a position in STLNW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

  • HBK Investments reported no remaining Starling Oncology, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
  • HBK Investments sold 14,000 Starling Oncology, Inc. Warrant shares in Q1 2022, an estimated $10K.
  • HBK Investments first reported a position in Starling Oncology, Inc. Warrant in Q4 2021 and held it in 1 quarter.
  • HBK Investments's Starling Oncology, Inc. Warrant position peaked at $10K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q1 2022.

Based on HBK Investments's 13F filing for Q1 2022, filed 16 May 2022.